Inventor · disambiguated record
Ann Barbier
Also filed as: BARBIER ANN · BARBIER ANN J
6 granted patents·7 pending applications·10 citations·filing 2002–2025
75Inventor score
Files withSHIRE HUMAN GENETIC THERAPIES5TRANSLATE BIO INC4AGIOS PHARMACEUTICALS INC1BARBIER ANN J1TAKEDA PHARMACEUTICALS CO1
Top patents by PatentIndex Score
13 records- 0189US11167043B2Composition and methods for treatment of ornithine transcarbamylase deficiencyTRANSLATE BIO INC·Filed 2018·Granted Nov 9, 2021·4 cites·4 claims
- 0280US9682129B2Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2012·Granted Jun 20, 2017·5 cites·29 claims
- 0372US12268754B2Composition and methods for treatment of ornithine transcarbamylase deficiencyTRANSLATE BIO INC·Filed 2021·Granted Apr 8, 2025·0 cites·18 claims
- 0472US10568941B2Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted Feb 25, 2020·1 cites·10 claims
- 0567US11357832B2Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfataseTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jun 14, 2022·0 cites·17 claims
- 0664US2025152739A1Composition and methods for treatment of ornithine transcarbamylase deficiencyTRANSLATE BIO INC·Filed 2025·Application pending·0 cites
- 0751US2024207254A1Methods for titrating mitapivatAGIOS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0851US2022323542A1TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTRTRANSLATE BIO INC·Filed 2020·Application pending·0 cites
- 0950US2018036386A1Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiiaSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Application pending·0 cites
- 1048US2015313971A1Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiiaSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Application pending·0 cites
- 1140US10578624B2Determination of glycosaminoglycan levels by mass spectrometrySHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Mar 3, 2020·0 cites·11 claims
- 1237US2004126817A1Gap junction permeability assayFiled 2002·Application pending·0 cites
- 1337US2007134753A1Assay for determining the activity of fatty acid amide hydrolaseBARBIER ANN J·Filed 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →